Antioxidant therapy in neurologic disease

N Delanty1, M A Dichter

  • 1Department of Clinical Neurological Sciences, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin 9, Ireland. normandelanty@eircom.net

Archives of Neurology
|September 15, 2000
PubMed

Insights

Oxidative injury is key in neurologic diseases. Antioxidant therapies show promise but require disease-specific approaches and early intervention for effectiveness in neurological disorders.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pharmacology

Background:

  • Oxidative stress and free radical damage are implicated in the pathogenesis of numerous human neurologic diseases.
  • Antioxidant (free radical scavenger) therapy offers a potential strategy for preventing, delaying, or mitigating these neurological disorders.
  • The complex biochemistry of oxidative pathobiology necessitates tailored antioxidant approaches for individual diseases.

Purpose of the Study:

  • To explore the potential role of antioxidant compounds in managing neurologic diseases.
  • To investigate the reasons behind mixed results in clinical trials of antioxidant therapies for neurological conditions.
  • To emphasize the need for disease-specific and timely antioxidant interventions.

Main Methods:

  • Review of in vitro and animal model studies on antioxidant compounds in neurologic disease.
  • Analysis of clinical trial outcomes for various antioxidants (e.g., vitamin E, N-acetylcysteine).
  • Examination of factors influencing antioxidant therapy efficacy, including dosage and disease-specific oxidative processes.

Main Results:

  • In vitro and animal studies suggest potential benefits of antioxidants in neurologic diseases.
  • Clinical trial results for antioxidants like vitamin E, tirilazad, N-acetylcysteine, and ebselen have been inconsistent.
  • Mixed outcomes may stem from inadequate dose-finding studies and a failure to characterize unique disease-specific oxidative mechanisms.

Conclusions:

  • Optimizing antioxidant therapy for neurologic diseases requires understanding and addressing individual disease biochemistry.
  • Early intervention with antioxidants in chronic neurologic disorders is crucial for achieving clinical benefits.
  • Future strategies may involve pre-disease screening and intervention in at-risk populations for neurodegenerative diseases.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...